Home > Resources > Whitepapers > Tale of Two Molecules

Tale of Two Molecules

February 20, 2018

Two molecules, both designed to treat the same condition, both with solubility challenges. Two biopharma companies racing to be first. Biopharma A chooses to move into trials as quickly as possible, while Biopharma B decides to address broader solubility concerns first. Who gets to market first may surprise you...download the infographic to find out.

Spotlight

Feldan Therapeutics

Since its beginning, Feldan has valued internal research with the aim of innovating, changing standards of care and redefining quality of life. With the recent development of the Feldan Shuttle, this approach is starting to show its promises. Feldan’s mission is to develop regenerative medicine therapeutic applications based on Feldan’s proprietary technology. The scientists at Feldan have developed the Feldan Shuttle, a protein-based technology platform that directly delivers proteins – such as nucleases or transcription factors - inside cells to specific cellular compartments.

OTHER WHITEPAPERS

Vendor Partnering in a Bioprocess Manufacturing and Supply Chain Ecosystem

whitePaper | August 30, 2022

Supply constancy, cost, sterility – even a subset of the factors that impact materials selection can be daunting for biopharmaceutical companies embark.

State of the Global Biotech Landscape: Where the Opportunities Lie

whitePaper | December 13, 2022

Over the last five years, the global biotech and pharmaceutical landscape has witnessed continued growth. The analysis period (2017-2022) encompasses a unique timeframe including the global COVID-19 pandemic.

Biosimilars – commercial best practices in the age of sustainability

whitePaper | November 4, 2019

Revenues from biologics increased by 70% from 2011 to 2016. Biologics account for 20-22% of total pharmaceutical spending. IQVIA estimates US biologics spending will reach $320bn by 2023

Cell and Gene Therapy Hot Buttons Series

whitePaper | September 27, 2022

Cell and Gene Therapy (CAGT) activity has increased dramatically in recent decades, especially in Chimeric Antigen Receptor T-Cell (CAR-T) clinical trials and therapy registrations. The IQVIA CAGT Hot Buttons series covers basic concepts in CAGT for newcomers to this field.

New Diagnostic Approaches for Undiagnosed Rare Genetic Diseases

whitePaper | April 16, 2020

Accurate diagnosis is the cornerstone of medicine; it is essential for informed care and promoting patient and family well-being. However, families with a rare genetic disease (RGD) often spend more than five years on a diagnostic odyssey of specialist visits and invasive testing that is lengthy, costly, and often futile, as 50% of patients do not receive a molecular diagnosis.

T Cell Expansion in Small Scale Bioreactors

whitePaper | October 28, 2022

Adoptive cell therapy (ACT), a branch of immunotherapy, offers a promising treatment for chronic viral infections and malignant diseases such as cancer [1]. This innovative approach involves the autologous or allogenic transplant of immune cells into the patient’s body.